Skip to main content
Premium Trial:

Request an Annual Quote

Toyobo Gene Analysis to Evaluate Crucell's Cell Generation Tech

NEW YORK (GenomeWeb News) – Dutch biotech company Crucell said today that Toyobo Gene Analysis will evaluate Crucell’s cell line technology for use in producing recombinant proteins for third-party customers.
 
Toyobo Gene Analysis is a wholly-owned subsidiary of Osaka, Japan-based Toyobo.
 
Crucell’s Star Technology contains elements that “enable stable and high-yield gene expression important to recombinant antibody and protein production in mammalian cells,” the company said. Crucell believes this technology could be used to increase production yields of recombinant proteins, which could lower the cost of producing them.
 
Financial terms of the agreement were not released.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.